Skip to Main Content

5,817

Views

11

CrossRef citations to date

0

Altmetric

Original Articles

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

David Strausa Memorial Sloan Kettering Cancer Center, New York City, NY, USACorrespondence[email protected]
View further author information

,

Graham Collinsb Oxford Cancer and Hematology Center, Churchill Hospital, Oxford, UKView further author information

,

Jan Walewskic Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, PolandView further author information

,

Pier Luigi Zinzanid Institute of Hematology Seragnoli, University of Bologna, Bologna, ItalyView further author information

,

Andrew Grigge Department of Clinical Haematology, Austin Hospital, Melbourne, AustraliaView further author information

,

Anna Suredaf Institut Català d'Oncologia-Hospitalet, Hospital Quirón Dexeus, Barcelona, SpainView further author information

,

Arpad Illesg University of Debrecen, Faculty of Medicine, Debrecen, HungaryView further author information

,

Tae Min Kimh Seoul National University Hospital, Seoul, Republic of KoreaView further author information

,

Sergey Alekseevi Petrov Research Institute of Oncology, St. Petersburg, RussiaView further author information

,

Lena Spechtj Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information

,

Valeria Buccherik Hematology Service, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, BrazilView further author information

,

Anas Younesa Memorial Sloan Kettering Cancer Center, New York City, NY, USAView further author information

,

Joseph Connorsl BC Cancer Centre for Lymphoid Cancer, Vancouver, CanadaView further author information

,

Andres Forero-Torresm Seattle Genetics, Bothell, WA, USAView further author information

,

Keenan Fentonm Seattle Genetics, Bothell, WA, USAView further author information

,

Ashish Gautamn Millennium Pharmaceuticals, Cambridge, MA, USAView further author information

,

Indra Purevjaln Millennium Pharmaceuticals, Cambridge, MA, USAView further author information

,

Rachael Liun Millennium Pharmaceuticals, Cambridge, MA, USA

https://orcid.org/0000-0001-6033-4510 View further author information

&

Andrea Gallaminio Research and Clinical Innovation, Antoine-Lacassagne Cancer Center, Nice, FranceView further author information